Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Merit Medical (MMSI) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 12.77% and 4.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merit Medical's (MMSI) Latest Launch to Boost Patient Outcome
by Zacks Equity Research
Merit Medical's (MMSI) latest well-designed tray is expected to simplify the thoracostomy procedure and reduce treatment time, especially in critical situations.
Merit Medical's (MMSI) SCOUT Bx Delivery System Gets FDA Nod
by Zacks Equity Research
Merit Medical's (MMSI) receipt of FDA clearance for the SCOUT Bx system can streamline treatment for cancer patients.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Merit Medical's (MMSI) Product Included in FDA's Program
by Zacks Equity Research
Receipt of the Breakthrough Device Designation for Merit Medical's (MMSI) Embosphere Microspheres is expected to improve patient outcome.
Merit Medical's (MMSI) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.
Merit Medical (MMSI) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 42% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Merit Medical (MMSI) Q4 Earnings Expected to Decline
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 14.75% and 2.95%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 14.31% and 3.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its progress in the WAVE study and a strong product portfolio.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.
Merit Medical (MMSI) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merit Medical's (MMSI) Q3 Earnings, Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI), in the third quarter, benefits from revenue growth in its Cardiovascular segment, and from the majority of the product categories within its Cardiovascular unit.
Merit Medical (MMSI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 18.18% and 2.36%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BDX or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. MMSI: Which Stock Is the Better Value Option?
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.
PDCO vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. MMSI: Which Stock Is the Better Value Option?
3 Promising MedTech Stocks to Snap Up in Second-Half 2021
by Trina Mukherjee
Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.
NextGen's (NXGN) New Partnership to Boost Patient Experience
by Zacks Equity Research
NextGen (NXGN) collaborates with Clinect Healthcare to extend patient-provider connection.
Veeva Systems' (VEEV) Cloud Applications Get Adopted by Emmes
by Zacks Equity Research
Veeva Systems' (VEEV) Development Cloud applications to aid in connected drug development.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.
Fresenius Medical's (FMS) Deal to Boost Home Dialysis in Japan
by Zacks Equity Research
Fresenius Medical (FMS) partners with JMS Co. Ltd. to provide innovative home dialysis therapies to the aging population in Japan to improve their wellbeing.